icon-folder.gif   Conference Reports for NATAP  
 
  Glasgow HIV
28 - 31 October 2018
Glasgow, UK
Back grey_arrow_rt.gif
 
 
 
Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial
 
 
  Reported by Jules Levin
Glasgow Oct 27-31 2018
 
Amandine Cournil, Charles Kouanfack, Sabrina Eymard-Duvernay, Serra Lem, Mireille Mpoudi-Ngole, Pierrette Omgba, Serge Tchokonte, Ginette Edoul Mbesse, Eitel Mpoudi-Ngole, Alexandra Calmy, Eric Delaporte, for the NAMSAL study group

1105181

1105182

Low-Dose (400-mg) Efavirenz vs Standard 600-mg Dose Studied, Found Non-Inferior Low-Dose (400-mg) Efavirenz Not Inferior to Standard 600-mg Dose
 
Population PK-PD Analysis of 400 mg vs. 600 mg Efavirenz Once Daily in Treatment-Na´ve HIV Patients at 48 Weeks: Results of the ENCORE1 Study
 
Efavirenz Dose and Genotype Do Not Affect 48-Week Response in Low/Standard-Dose Trial - written by Mark Mascolini - (05/20/14)
 
Dolutegravir Superior to Efavirenz at 144 Weeks in SINGLE Trial
 
Dolutegravir plus Abacavir-Lamivudine vs Efavirenz/TDF/FTC Once Daily for the Treatment of HIV-1 Infection
 
48 Week Bone Marker Changes in Dolutegravir (DTG; GSK1349572) Plus Abacavir/Lamivudine (ABC/3TC) vs Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial - (09/13/13)
 

1105183

1105184

1105185

1105186

1105187

1105188

1105189